Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.66 |
| ▸ | NPC1 | O15118 | 9/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.66 |
| ▸ | RELA | Q04206 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 14/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970198 | 0.83 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL1692138 | 0.83 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL12692485 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL4147815 | 0.83 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL969616 | 0.83 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL30059210 | 0.83 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL5773733 | 0.83 | TP53 (0.68) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL2496897 | 0.83 | TP53 (0.68) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| Bromide SCHEMBL3869607 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL4781521 | 0.80 | NPC1 (0.61) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115323409-B | Method for electrochemically synthesizing asymmetric double heteroaromatic compounds | 南京工业大学 | 2025-05-23 | — | — | CN | disclosed |
| CN-115323409-A | Method for electrochemically synthesizing asymmetric double-hetero aromatic hydrocarbon compound | 南京工业大学 | 2022-11-11 | — | — | CN | disclosed |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2021-09-30 | — | — | US | disclosed |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NATIONAL INSTITUTES OF HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980969-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | SOUTHERN RES INST (US) | 2016-01-28 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | ABBVIE INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008063287-A2 | NOVEL IMIDAZOTHIAZOLES AND IMIDAZOXAZOLES | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| EP-1809636-A1 | SYNTHESIS OF IMIDAZOOXAZOLE AND IMIDAZOTHIAZOLE INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006044869-A1 | SYNTHESIS OF IMIDAZOOXAZOLE AND IMIDAZOTHIAZOLE INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1633758-A2 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110990-A2 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022691-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 33/4885NPC1 489/4885RAB9A 2424/4885 |
| US-20200171040-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885NPC1 467/4885RAB9A 2402/4885 |
| US-20190083505-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885NPC1 467/4885RAB9A 2402/4885 |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | SMN1; SMN2 2415/4885NPC1 2774/4885RAB9A 1851/4885 |
| US-20080161341-A1 | Novel imidazothiazoles and imidazoxazoles | MAP3K1, MAP3K19, MAP3K5 | SMN1; SMN2 3838/4885NPC1 2227/4885RAB9A 3058/4885 |
| US-20210299131-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885NPC1 467/4885RAB9A 2402/4885 |
| US-10953017-B2 | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such | NFKBIA, NFRKB, TFEB | SMN1; SMN2 29/4885NPC1 467/4885RAB9A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.